CTMX
CytomX Therapeutics, Inc.
3.67
2 x 2.60
2 x 4.67
bid
ask
+
0.07
2.08%
09:51 AM
timesize
Ytd-13.73%
1y48.19%
3.60
day range
3.68
1.72
52 week range
8.21
Open3.65Prev Close3.60Low3.60High3.68Mkt Cap800.06M
Vol211.11KAvg Vol4.45MEPS-0.52P/EN/AForward P/E-9.74
Beta2.48Short Ratio1.78Inst. Own75.69%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0650-d Avg3.63200-d Avg4.111yr Est13.67

CTMX News

CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

benzinga.com
CytomX Expands Collaboration And Licensing Agreement With Regeneron To Create Conditionally-Activate

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immu

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
globenewswire.com
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Condit

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immu

CytomX Therapeutics: Cashed Up With Catalysts Ahead
seekingalpha.com
CytomX Therapeutics: Cashed Up With Catalysts Ahead

In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although t

CytomX Therapeutics to Present at Upcoming June Investor Conferences
globenewswire.com
CytomX Therapeutics to Present at Upcoming June Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTM

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
globenewswire.com
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affa

SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTM

benzinga.com
HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Lowers Price Target to $11

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) wi

CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
seekingalpha.com
CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript

CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
zacks.com
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.1 per share versus the Zacks Consens

benzinga.com
CytomX Therapeutics Q1 EPS $(0.10) Beats $(0.20) Estimate, Sales $10.258M Beat $4.713M Estimate

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.10) per share which beat the anal

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
globenewswire.com
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) Ep

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
globenewswire.com
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: C

Small Cap or Megacap: Which Healthcare Stock Is Right for You?
fool.com
Small Cap or Megacap: Which Healthcare Stock Is Right for You?

Healthcare companies with different market caps offer different rewards and challenges.

Stock Traders Buy High Volume of CytomX Therapeutics Put Options (NASDAQ:CTMX)
defenseworld.net
Stock Traders Buy High Volume of CytomX Therapeutics Put Options (NASDAQ:CTMX)

CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) was the target of some unusual options tr

CytomX Therapeutics (NASDAQ:CTMX) & Adagene (NASDAQ:ADAG) Financial Comparison
defenseworld.net
CytomX Therapeutics (NASDAQ:CTMX) & Adagene (NASDAQ:ADAG) Financial Comparison

Adagene (NASDAQ: ADAG - Get Free Report) and CytomX Therapeutics (NASDAQ: CTMX - Get Free Report) ar

Assenagon Asset Management S.A. Sells 137,271 Shares of CytomX Therapeutics, Inc. $CTMX
defenseworld.net
Assenagon Asset Management S.A. Sells 137,271 Shares of CytomX Therapeutics, Inc. $CTMX

Assenagon Asset Management S.A. decreased its holdings in shares of CytomX Therapeutics, Inc. (NASDA

benzinga.com
Piper Sandler Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12

Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overwei

CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up  After Analyst Upgrade
defenseworld.net
CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade

CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) gapped up prior to trading on Thursday af

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

benzinga.com
Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $16

Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and r

benzinga.com
Jefferies Maintains Buy on CytomX Therapeutics, Raises Price Target to $16

Jefferies analyst Roger Song maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises th

Why Is CytomX Therapeutics Stock Falling On Wednesday?
benzinga.com
Why Is CytomX Therapeutics Stock Falling On Wednesday?

On Tuesday, CytomX Therapeutics announced a public offering of 45.9 million shares at $5.30 per shar

Why Is CytomX Therapeutics Stock Falling On Wednesday?
benzinga.com
Why Is CytomX Therapeutics Stock Falling On Wednesday?

CytomX stock falls after $250 million share sale, even as new colorectal cancer data shows strong re

CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level
seekingalpha.com
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level

CytomX Therapeutics (CTMX) has generated significant excitement with strong early data for varsetatu

benzinga.com
Guggenheim Maintains Buy on CytomX Therapeutics, Raises Price Target to $15

Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and rai

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warran

SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CT

CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
zacks.com
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data

CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastat

benzinga.com
Wedbush Maintains Outperform on CytomX Therapeutics, Raises Price Target to $11

Wedbush analyst Robert Driscoll maintains CytomX Therapeutics (NASDAQ:CTMX) with a Outperform and

Boothbay Fund Management LLC Buys Shares of 1,237,057 CytomX Therapeutics, Inc. $CTMX
defenseworld.net
Boothbay Fund Management LLC Buys Shares of 1,237,057 CytomX Therapeutics, Inc. $CTMX

Boothbay Fund Management LLC purchased a new position in CytomX Therapeutics, Inc. (NASDAQ: CTMX) du

Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
fool.com
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Da

CytomX Therapeutics (CTMX +44.44%), a biotech company that develops conditionally activated biologic

benzinga.com
CytomX Therapeutics Files Prospectus For Potential Offerings Of Stock, Debt, Warrants And Units

Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell the securities identifi

benzinga.com
CytomX Therapeutics Announces Public Offering Of $250M In Stock And Pre-Funded Warrants

In addition, CytomX expects to grant the underwriters a 30-day option to purchase up to an additiona

12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally
benzinga.com
Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally

CytomX Therapeutics stock jumps in premarket trading after Phase 1 data for Varseta-M showed tumor r

benzinga.com
HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Raises Price Target to $17

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) wi

Crude Oil Down 4%; Dollar Tree Earnings Top Views
benzinga.com
Crude Oil Down 4%; Dollar Tree Earnings Top Views

benzinga.com
JP Morgan Upgrades CytomX Therapeutics to Overweight, Raises Price Target to $12

JP Morgan analyst Anupam Rama upgrades CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Overweig

Nebius Group, CytomX Therapeutics, National Storage Affiliates Trust And Other Big Stocks Moving Higher On Monday
benzinga.com
Nebius Group, CytomX Therapeutics, National Storage Affiliates Trust And Other Big Stocks Moving Hig

Dow Jones index up 500 points; Nebius Group NV shares rise 12.7% on AI agreement with Meta Platforms

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com
Market-Moving News for March 16th

NBIS: 17% | Nebius Announced 5-Year $12B AI Infrastructure Agreement With Meta To Provide Dedicated

Earnings Scheduled For March 16, 2026
benzinga.com
Earnings Scheduled For March 16, 2026

benzinga.com
CytomX Therapeutics Announces Phase 1 Expansion Data For EpCAM PROBODY ADC, Varseta-M In Late-Line M

- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W

benzinga.com
CytomX Therapeutics Q4 EPS $(0.22) Misses $(0.09) Estimate, Sales $663.000K Miss $7.900M Estimate

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.22) per share which missed the an

CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
benzinga.com
CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's M

CytomX Therapeutics (CTMX) will release its Q4 earnings on March 16, with analysts expecting a loss

Where CytomX Therapeutics Stands With Analysts
benzinga.com
Where CytomX Therapeutics Stands With Analysts

benzinga.com
Guggenheim Reiterates Buy on CytomX Therapeutics, Maintains $10 Price Target

Guggenheim analyst Michael Schmidt reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Buy and ma

benzinga.com
Cantor Fitzgerald Maintains Overweight on CytomX Therapeutics, Raises Price Target to $10

Cantor Fitzgerald analyst Olivia Brayer maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overwe

benzinga.com
Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $10

Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and r

benzinga.com
Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $8

Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and r

benzinga.com
Guggenheim Initiates Coverage On CytomX Therapeutics with Buy Rating, Announces Price Target of $10

Guggenheim analyst Michael Schmidt initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a